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Abstract
The V3 region of both HIV-1 gp120 and HIV-2 gp125 surface glycoprotein has been described as a
target for neutralizing antibodies. In this study a conformation-sensitive (3C4) and a linear site-
specific (7C8) anti-HIV-2 V3 monoclonal antibody (mAb) were characterized. The neutralization
capacity of the purified mAbs and their respective papain-generated Fab fragments was analyzed.
The Fabs were further characterized by sequence analysis. Our results demonstrate that neither
purified mAbs were capable of neutralizing HIV-2, while intact Fab fragments from both mAbs
blocked in vitro infection of HIV-2 isolates. Moreover, the conformation sensitive 3C4 Fab
neutralized both subtype A and B HIV-2 isolates and SIVsm. Sequence analysis of the hypervariable
regions of 3C4 Fab and 7C8 Fab revealed that the third CDR of the heavy chain (CDRH3) of the
antibodies was not as long as many of the previously characterized neutralizing antibodies. Our
findings suggest that whole 7C8 and 3C4 mAbs are sterically hindered from neutralizing HIV-2,
whereas the smaller size of Fab fragments enables access to the V3 region on the virion surface.
Findings
The HIV-1 V3 region has been identified as a target site
recognized by neutralizing antibodies [1]. Monoclonal
antibodies (mAbs) targeting conformational epitopes
within the V3 region have been demonstrated to neutral-
ize primary HIV-1 isolates [2-5]. Furthermore, anti-HIV-1
V3-specific mAbs have recently been shown to have broad
cross-reactivity, which was dependent on the extent of
masking of the V1/V2 regions and the sequence at the
crown of the V3-loop [6].
Neutralizing antibodies have been reported to bind
within the HIV-2 V3 region [7,8], with the FHSQ residues
at the tip of the V3-loop [9]. However, mAbs recognizing
the linear (FHSQ) site on gp125 could not neutralize HIV-
2 isolates [9,10]. Conversely, a conformational epitope
composed of FHSQ (amino acids 315–318 in HIV-2 ISY
clone) and WCR (amino acids 329–331) has been
described in the V3 region of gp125 [9,11], where mAbs
recognizing conformational epitopes in the gp125 V3
region could neutralize HIV-2 isolates [9,12]. While the
exposure of the V3 region in HIV-1 is debated, the accessi-
bility of neutralizing sites on HIV-2 V3 region has not
been as extensively characterized as for HIV-1.
Previously, two hybridoma cell-lines have been isolated
from mice immunized with two overlapping peptides of
HIV-2 spanning the center and C-terminus of the V3
region [9]. The hybridoma expressing the 3C4 mAb recog-
nized both peptides, while the 7C8 mAb recognized only
the center of the V3 region. Mouse ascitic fluid containing
3C4 has been reported to neutralize different isolates of
HIV-2 at a dilution of 1:20, whereas the mouse ascitic
fluid containing 7C8 had no neutralizing effect. Further
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characterization of the binding of these two mAbs to
recombinant gp125 indicated that 3C4 is conformation
sensitive while 7C8 binds to a linear site [13].
In this study, the HIV-2 neutralization capacity of protein
A-purified 3C4 and 7C8 mAbs was analyzed. A neutraliza-
tion assay employing phytohemagglutinin-stimulated
PBMCs (peripheral blood mononuclear cells) was used
[14]. Two-fold serial dilutions of mAb starting at 100 μg/
ml were incubated for one hour at 37°C with a minimum
of 15 TCID50 (50% tissue culture infectious dose) tissue
culture supernatant from virus infected cells. PBMCs (105)
were then added to the mix and incubated overnight at
37°C. The medium was changed with fresh IL-2 contain-
ing medium on the following day and on day 4. Seven
days after infection, supernatants were collected and ana-
lyzed for HIV-2 antigen by a capture ELISA [15]. The neu-
tralization concentration was defined as the
concentration where a 80% reduction or more of optical
density at 490 nm in the culture supernatant was seen as
compare to the negative control (i.e. IC80). To determine
the virus inoculum dose, a TCID50 titration was performed
in parallel to each neutralization experiment.
Contrary to what has been reported previously for 3C4, up
to 100 μg/ml of the purified mAbs did not neutralize any
of the HIV-2 isolates tested (data not shown). This could
be explained by the fact that ascitic fluid contains > 10
mg/ml of mAb as well as other components that could
alter the neutralization effect.
The lack of neutralization capacity displayed by both the
linear-specific (7C8) and conformation-sensitive (3C4)
antibodies may be related to the accessibility of the
epitope recognized by these antibodies. Previous reports
on the potent neutralization effect of Fabs compared to
mAbs [16,17] prompted us to study the effect of the size
of mAbs on HIV-2 neutralization capacity. Both 7C8 and
3C4 were digested using papain, and the different diges-
tion products were separated using size-exclusion chro-
matography (Amersham Biosciences). Fab fragments were
purified using Superose-12 and eluted in a single peak
using 20 mM Tris buffer. Fractions from this peak were
pooled and used in the neutralization assays. HIV-2SBL6669
is a CXCR4 co-receptor-using isolate belonging to subtype
A. In contrast to the undigested mAbs, both 3C4 and 7C8
Fabs were capable of neutralizing the homologous HIV-
2SBL6669 isolate (including the V3 sequence the mAbs were
generated against) and the hetrologous CCR5 co-receptor-
using laboratory-adapted isolate HIV-2K135. Table 1 indi-
cates the concentrations of 3C4 and 7C8 Fabs required to
neutralize HIV-2 as determined on at least two different
occasions. HIV-2SBL6669 and HIV-2K135 could be neutral-
ized by both 7C8 and 3C4 Fabs, where 3C4 Fab was capa-
ble of viral neutralization at as low a concentration as 0.16
μg/ml. The concentration of 3C4 Fab required for neutral-
ization was dependent on the virus inoculum dose,
whereas 0.63 μg/ml of 7C8 Fab was required in the cases
where neutralization was observed. In all the neutraliza-
tion assays, the 3C4 Fab appeared to be twice as potent in
neutralization as was the 7C8 Fab. Furthermore, all the
primary isolates tested, regardless of co-receptor usage,
were neutralized by the 3C4 Fab. Since the neutralization
sites recognized by 3C4 are conserved in both HIV-2 and
SIV, the neutralization of SIVsm was also assessed. SIVsm
was as efficiently neutralized by the 3C4 Fab as the other
HIV-2 isolates tested.
The level of neutralization varied depending on the qual-
ity of the Fab produced by the papain digestion, where the
Table 1: In vitro virus neutralization exhibited by 7C8 Fab and 3C4 Fab fragments given as the concentration of Fab needed for IC80 
neutralization.
Virus Fab Fragment
Isolate Subtype Coreceptor
usage+
TCID50 7C8
(μg/ml)
3C4
(μg/ml)
HIV-2SBL6669 A CCR3, CXCR4 42 0.63 0.31
15 0.63 < 0.16
HIV-2K135 unknown CCR5* 435^ - 6.25
18 0.63 0.31
HIV-21682 A CCR1, CCR3, CCR5 28 - 6.25
HIV-21653 B CCR5 18 - 6.25
HIV-22298 A CCR5 18 - 12.50
SIVsm n/a CCR5, BOB 44 - 3.13
+ Co-receptor usage according to Mörner et al. [11] and Vödrös et al. [30].
* Determined by Jose M. Marcelino (personal communication).
n/a Not applicable.
^ Very high virus inoculum dose.
- No neutralization observed up to 100 μg/ml.Virology Journal 2008, 5:96 http://www.virologyj.com/content/5/1/96
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Fab production, purification and sequencing Figure 1
Fab production, purification and sequencing. A. Chromatogram of separation of papain digestion products using Super-
dex-75. The undigested mAb (I) is eluted first, followed by the Fab fragments (II & III) and the Fc fragments along with other 
small digestion products (IV) are collected last. Bottom right: Analysis of fractions 1–5 on 10% SDS gel demonstrate separation 
of the Fab fragments (47 kDa) from the over-digested Fab fragments (≈ 37 kDa). Top right: Schematic diagram of mAb digestion 
by papain as previously described in literature [18]. The bold arrow indicates were papain digests primarily before the cysteine-
bridges on mAb (I). The papain can also digest the Fab fragment produced (II), as indicated by dashed arrow. The digested Fab 
(III) may be missing one of the Fv regions. B. The variable regions of 7C8 and 3C4 heavy and light chains, are aligned respec-
tively. The CDR regions as indicated by immunoglobulin superfamily database http://imgt.cines.fr[31] are shaded.
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digestion efficiency varied between experiments. To fur-
ther analyze the variation in neutralization efficiency of
the generated Fab fragments, Superdex 75 size-exclusion
chromatography column was used. Figure 1A depicts the
separation of digestion products, where Fabs (peak II) are
separated from over-digested Fab fragments (peak III).
Fab fragments of molecular weight ~47 kDa were capable
of neutralizing HIV-2, whereas over-digested Fab frag-
ments with a lower molecular weight of ~37 kDa were not
(data not shown). The preferential papain digestion sites
on antibodies is illustrated in the schematic diagram in
Figure 1A. As previously described, over-digestion by
papain can release Fv from Fab fragments [18,19], produc-
ing a digested Fab fragment incapable of viral neutraliza-
tion.
The mechanism underlying the more potent neutralizing
effect of Fab fragments has been previously correlated
with the smaller size of Fab fragments compared to the
size of whole IgG, where steric factors could limit the
accessibility to neutralizing epitopes [16]. Previous
reports have also described different neutralization mech-
anisms between mAbs and Fabs at the attachment or
fusion of the virus with target cells [20,21].
To characterize the Fab fragments, the variable regions of
7C8 and 3C4 were sequenced according to their subtypes.
Sub-typing of 7C8 and 3C4 revealed that both mAbs have
kappa light chains and that they belong to subtypes IgG1
and IgG2a, respectively. Alignment of 7C8 and 3C4 varia-
ble regions (Figure 1B) indicated that the light chains of
both Fabs are more conserved (93% identity) than the
heavy chain (53% identity). The predicted CDR loops are
indicated in Figure 1B, where the CDR3 loop of 7C8 and
3C4 heavy chains consists of 13 and 11 residues, respec-
tively.
The third CDR of the heavy chain (CDRH3) of an anti-
body plays a distinctive role in determining antibody spe-
cificity [22]. Sequence analysis of 7C8 CDRH3 revealed a
comparatively long region of 13 amino acids (aa),
whereas the average length of CDRH3 in mice is between
8 and 9 aa and <11% of mice antibodies have a CDRH3
length of >13 aa [22,23]. Most human anti-gp120 anti-
bodies have CDRH3 of >15 aa [24], as exemplified by the
neutralizing mAbs/Fab, 17b, b12, 2F5, and X5 which rec-
ognize different epitopes on gp120 and have CDRH3
lengths of 19, 18, 22, and 22 aa respectively [25-29].
Therefore, we do not believe that the comparatively longer
CDRH3 regions of 3C4 and 7C8 would play a strong role
in the viral neutralization.
In conclusion, a confirmation sensitive HIV-2 V3 specific
Fab was shown to neutralize both HIV-2 A and B subtypes
and SIVsm. Further analyses indicate that the smaller size
of intact Fab fragments may be a determining factor for
HIV-2 V3-specfic viral neutralization. These results could
provide clues to small molecule anti-HIV inhibitors.
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